Tube Investments of India Limited (TII) has announced a further infusion of capital into its subsidiary, 3xper Innoventure Limited. Through a supplementary agreement executed on April 23, 2026, TII will invest ₹75 crore, while Mr. N Govindarajan will contribute ₹25 crore. This total ₹100 crore investment, issued through Compulsorily Convertible Preference Shares (CCPS), is aimed at scaling up 3xper’s operations in the pharmaceutical contract development and manufacturing sector.
Boosting Growth in Pharmaceutical Operations
The latest capital infusion marks a significant milestone for 3xper Innoventure Limited, which specializes in Contract Development and Manufacturing Operations (CDMO) within the pharmaceutical industry. By securing an additional ₹100 crore in funding, the company is well-positioned to accelerate its expansion and operational capacity alongside its existing subsidiary.
Details of the Capital Infusion
As part of the supplementary agreement, the investment is structured through the issuance of 1 crore CCPS at a face value of ₹100 per share. The breakdown of this investment includes ₹75 crore from Tube Investments of India Limited (TII) and ₹25 crore from Mr. N Govindarajan. This transaction ensures that TII maintains its strategic interest in the growth trajectory of its subsidiary.
Commitment to Future Development
TII, which already holds a substantial equity and CCPS stake in 3xper, remains committed to the entity’s long-term business objectives. The closing of this transaction is subject to the satisfactory completion of specific conditions precedent outlined in the supplementary agreement. This strategic move highlights the company’s focus on diversifying its investment portfolio into the high-growth pharmaceutical services sector.
Source: BSE
